GÖRG has advised Medigene AG on the conclusion of an agreement for a standby equity purchase agreement (SEPA) with a fund managed by Yorkville Advisors Global, LP (‘Yorkville’).
Medigene AG is a biotechnology company that was founded in 1994, went public in 2000, and is headquartered in Martinsried near Munich, with a US subsidiary in San Diego, California. The company is developing highly innovative immunotherapies for the treatment of solid cancer tumours. Medigene is focusing on differentiated T cell-based therapeutic approaches.
The SEPA enables the company to sell new shares with a total volume of up to 15 million euros from authorised capital to Yorkville at its own discretion, excluding shareholders' subscription rights. Yorkville is obliged to subscribe for and acquire the requested number of shares in accordance with the terms of the SEPA. The transaction can take place in several tranches. The agreement has a term of 36 months from the date of signing.
Medigene AG once again relied on the proven transaction team led by GÖRG partner Dr Bernt Paudtke. The law firm has already provided the biotech company with legal advice on capital measures on several occasions – including a recently completed capital increase with gross proceeds of €5.9 million.
Advisors Medigene AG
GÖRG Partnerschaft von Rechtsanwälten mbB
Dr Bernt Paudtke (Lead, Partner, Stock Corporation and Capital Market Law/Corporate, Munich)
Dr Lutz Pospiech (Partner, Stock Corporation and Capital Market Law/Corporate, Munich)
Tobias Reichenberger (Associated Partner, Stock Corporation and Capital Market Law/Corporate, Munich)
Medigene AG
Legal Department
Ralph Schäfer (General Counsel)
Nicole Löffler (Manager Legal Affairs)
